New drug hope for rare kidney disease: daratumumab trial launches
NCT ID NCT05654506
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests a drug called daratumumab in 40 people with a rare kidney condition called PGNMID, where abnormal proteins damage the kidneys. Participants receive weekly injections for 8 weeks, then every two weeks for another 8 weeks. The goal is to see if the drug can reduce protein in the urine and improve kidney health, while monitoring for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- daratumumab
- What this could lead to
- If successful, this could provide a new treatment option for people with this rare kidney disease, potentially reducing protein in the urine and preserving kidney function.
- What could go wrong
- This is an early Phase 2 trial with only 40 participants, so results may not apply to everyone. Daratumumab can cause serious infections and other side effects, and it is not a cure—patients may still need ongoing care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROLIFERATIVE GLOMERULONEPHRITIS WITH MONOCLONAL IGG DEPOSITS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic
RECRUITINGJacksonville, Florida, 32224, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Oregon Health and Science University
NOT_YET_RECRUITINGPortland, Oregon, 97239, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University North Carolina at Chapel Hill
RECRUITINGChapel Hill, North Carolina, 27599, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.